EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: A JET observational study in Japanese clinical practice

Tsukasa Matsubara, Kou Katayama, Akira Sagawa, Masaaki Yoshida, Takeshi Mitsuka, Keisuke Hashimoto, Tomomaro Izumihara, Masakazu Kondo, Tomomasa Izumiyama, Nobumasa Miyake, Ichiro Yoshii, Motohiro Oribe und 2 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/road027 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Tsukasa Matsubara und 13 weiteren Autor:innen. Beteiligte Einrichtung: Matsubara Mayflower Hospital, Hyogo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Biosimilar Pharmaceuticals, Arthritis, Rheumatoid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the usefulness and onset of nocebo effects after switching from the original etanercept (ETN) to a biosimilar (BS) in routine clinical practice at rheumatology clinics in Japan (13 sites).

Methods

A total of 165 patients (87.0% women, age = 57.88 ± 15.07 years, and disease duration = 10.32 ± 7.71 years), whose low disease activity was maintained with the original ETN for ≥12 weeks, and who agreed to switch treatment to its BS, were included. The end-points were disease activity score 28 (DAS28)-C-reactive protein and DAS28-erythrocyte sedimentation rate.

Results

No significant difference was observed between the changes in DAS28-C-reactive protein and DAS28-erythrocyte sedimentation rate >12 weeks before switching and >12 weeks after switching (P = 0.132 and 0.334, respectively). The treatment continuation rate during the 52 weeks after switching to BS was 97.3%. During this period, BS was discontinued in only four patients, and no nocebo effects were suspected in these four patients.

Conclusion

Switching from ETN to BS was effective even in routine clinical practice at rheumatology clinics in Japan, and no nocebo effects were observed. Sufficient explanations to patients by rheumatologists and the additional payment for drug costs between patients at hospital visits effectively improved the continuation rate without any nocebo effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsBiosimilar PharmaceuticalsArthritis, RheumatoidHumansFemaleAdultMiddle AgedAgedMaleEtanerceptNocebo EffectJapanC-Reactive ProteinTreatment Outcome

Stichwörter der Autor:innen

Nocebo effectsbiosimilaretanerceptobservational studyrheumatoid arthritis

Substanzen

EtanerceptAntirheumatic AgentsBiosimilar PharmaceuticalsC-Reactive Protein

Autor:innen und Institutionen

  • Matsubara Mayflower Hospital, Hyogo, Japan.
  • Katayama Orthopedic Rheumatology Clinic, Hokkaido, Japan.
  • Sagawa Akira Rheumatology Clinic, Hokkaido, Japan.
  • Yoshida Orthopaedic Surgery and Rheumatology Clinic, Iwate, Japan.
  • Mitsuka Rheumatism Clinic, Chiba, Japan.
  • Hashimoto Clinic for Rheumatic Diseases, Hyogo, Japan.

Zitieren

APA

Matsubara, T., Katayama, K., Sagawa, A., Yoshida, M., Mitsuka, T., Hashimoto, K., Izumihara, T., Kondo, M., Izumiyama, T., Miyake, N., Yoshii, I., Oribe, M., Momohara, S., & Funahashi, K. (2024). Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: A JET observational study in Japanese clinical practice. Modern Rheumatology. https://doi.org/10.1093/mr/road027

Vancouver

Matsubara T, Katayama K, Sagawa A, Yoshida M, Mitsuka T, Hashimoto K, et al. Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: A JET observational study in Japanese clinical practice. Modern Rheumatology. 2024. doi:10.1093/mr/road027

BibTeX
@article{Matsubara2024,
  author = {Matsubara, Tsukasa and Katayama, Kou and Sagawa, Akira and Yoshida, Masaaki and Mitsuka, Takeshi and Hashimoto, Keisuke and Izumihara, Tomomaro and Kondo, Masakazu and Izumiyama, Tomomasa and Miyake, Nobumasa and Yoshii, Ichiro and Oribe, Motohiro and Momohara, Shigeki and Funahashi, Keiko},
  title = {Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: A JET observational study in Japanese clinical practice},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road027}
}
Kostenlos starten →